The short version: tirzepatide and semaglutide are both injectable medications that quiet appetite and slow how fast your stomach empties. The difference is how many switches they flip. Semaglutide activates one gut-hormone receptor. Tirzepatide activates two. In the one large trial that put them head to head, the two-receptor drug produced more weight loss. That does not automatically make it the right drug for you - cost, side-effect tolerance, and what your labs say all matter. Here is the full picture.
What each drug actually is
Semaglutide is a GLP-1 receptor agonist. GLP-1 is a hormone your gut releases after you eat. It tells your brain you are full, slows gastric emptying, and improves how your pancreas releases insulin. Semaglutide is the molecule inside Ozempic and Wegovy. You can read the full mechanism, dosing, and side effects on our semaglutide science page.
Tirzepatide is a dual GIP and GLP-1 receptor agonist. It does everything semaglutide does, and it adds a second pathway: GIP, another incretin hormone that appears to improve insulin sensitivity and how your body handles fat. Tirzepatide is the molecule inside Mounjaro and Zepbound. The dual GIP and GLP-1 mechanism, plus the full dosing chart, is covered on our tirzepatide science page.
Two receptors instead of one is not marketing. It is the structural reason the two drugs behave differently in the data.
Weight loss: what the trials show
You have to separate the individual trials from the head-to-head trial, because they measure different things.
In its pivotal weight-loss trial, semaglutide at 2.4 mg weekly produced roughly 15% mean body-weight reduction at 68 weeks in adults without diabetes. Tirzepatide in its own pivotal trial produced up to about 21% at the 15 mg dose over 72 weeks. Those are different trials with different populations, so you cannot subtract one number from the other and call it the gap.
The trial that does let you compare them directly randomized people to one drug or the other. Tirzepatide came out ahead - roughly 20% versus 14% mean weight loss, with a larger share of participants reaching the 15% and 20% thresholds. On the current evidence, tirzepatide is the more powerful weight-loss molecule on average.
"On average" is doing real work in that sentence. Trial means describe populations. They do not predict the person in front of you. We have patients who plateaued on tirzepatide and responded well to semaglutide, and the reverse.
Side effects: more alike than different
Both drugs share the same dominant side effects, and they come from the same place - the slowed gut. Nausea, diarrhea, constipation, and reflux lead the list. Most of it is dose-dependent and shows up during titration, then settles as your body adapts.
- Nausea is the most common complaint on both. It is worst in the first weeks after each dose increase.
- Constipation and diarrhea are common on both and usually manageable with hydration, fiber, and pace of titration.
- Gallbladder issues and pancreatitis are uncommon but real risks for both drugs and a reason to report severe, persistent abdominal pain immediately.
- Both carry a boxed warning regarding thyroid C-cell tumors based on rodent data. Neither is appropriate if you or your family have a history of medullary thyroid carcinoma or MEN2.
Head-to-head side-effect rates are broadly similar. The bigger driver of how you feel is not which drug you pick - it is how fast you escalate the dose. Aggressive titration is where most of the misery comes from, and it is the part a transactional prescriber gets wrong.
Dosing and titration
Both are once-weekly subcutaneous injections, and both start low and step up on a schedule to limit side effects.
Semaglutide for weight management steps up over months toward a 2.4 mg maintenance target. Tirzepatide steps up toward 5, 10, or 15 mg depending on response and tolerance. The principle is identical: the dose that works is the lowest one that gets you steady progress without making you miserable, not the maximum on the label. Your provider sets and adjusts your titration schedule based on how you respond.
Cost and the compounded question
Price is often the deciding factor, and it cuts in semaglutide's favor. Branded versions of both are expensive without insurance coverage, and coverage for weight loss is inconsistent.
Compounded versions, prescribed when clinically appropriate, are typically billed by the pharmacy at cost. Compounded semaglutide generally runs less per month than compounded tirzepatide, because tirzepatide is the newer, more complex molecule. If two drugs would both work for you and budget is tight, semaglutide is usually the more affordable path. If maximal weight loss is the priority and cost is workable, tirzepatide has the edge.
One caution worth stating plainly: the compounding landscape shifts with FDA shortage status and regulation. A responsible prescriber tracks that and tells you when something changes. Price should never be the only input - a cheaper drug that does not fit your physiology is not a deal.
So which one should you take?
Tirzepatide tends to be the better starting point when:
- Maximal weight loss is the goal and cost is manageable
- You have significant insulin resistance - the GIP pathway may help
- You did not get enough response from a GLP-1-only drug
Semaglutide tends to be the better starting point when:
- Affordability is a primary constraint
- You want the molecule with the longest real-world track record for weight management
- You tolerated it well before, or expect to be sensitive to side effects and want a single-pathway drug
For most people the honest answer is that either drug will work, and the choice comes down to cost, tolerance, and what your metabolic labs reveal. Which is exactly the part most online clinics skip.
The question that comes before "which drug"
Here is what gets lost in every tirzepatide-versus-semaglutide debate online: the drug is the easy decision. The hard, important decision is whether your weight is being driven by something the medication will not fix on its own - untreated thyroid dysfunction, severe insulin resistance, a hormone deficiency, or a metabolic picture that needs more than appetite suppression.
That is why every GLP-1 protocol at KAYU starts with labs, not a prescription. Fasting insulin, HOMA-IR, HbA1c, full thyroid, ApoB, liver and kidney markers, a complete blood count. Your provider reads it as a system before recommending a molecule. You can see what a complete workup includes on our bloodwork page, and the full clinical picture of medical weight loss on our weight-loss condition page.
The other half most clinics never mention is muscle. Rapid weight loss on either drug strips lean mass along with fat unless you actively protect it with protein and resistance training. A protocol without a muscle-preservation plan and a defined off-ramp is half a protocol.
Frequently asked questions
Is tirzepatide just a stronger semaglutide?
Not exactly. Tirzepatide activates a second receptor (GIP) that semaglutide does not touch, and on average it produces more weight loss in trials. But "stronger" is not the same as "better for you" - the right drug depends on your labs, your budget, and how you tolerate side effects.
Can you switch from semaglutide to tirzepatide?
Yes, switching is common and is done under provider guidance, usually restarting titration at a low tirzepatide dose rather than matching the old dose. People often switch when they plateau or want more weight loss. The reverse switch happens too, often for cost or tolerability.
Which has fewer side effects?
They are broadly similar. Both cause nausea, constipation, and diarrhea that are worst during dose increases and usually improve with time and slower titration. The pace of titration matters more than which drug you choose.
Which is cheaper?
Semaglutide is generally the more affordable of the two, especially in compounded form, because tirzepatide is the newer and more complex molecule.
Read the full mechanisms on our GLP-1 program page before your consult.
Take the 2-minute KAYU assessment and your provider will tell you which molecule fits your metabolic profile - and whether a GLP-1 is even the right first move.
This article is educational. It does not substitute for a provider-patient relationship. Tirzepatide and semaglutide are prescription medications with contraindications and side effects your provider will review during your consult. Individual results vary.